National Science Foundation

Eascra Biotech specializes in developing DNA-inspired, nanoparticle-based delivery systems for targeted therapeutic treatment. Their platform, based on Janus base nanomaterials, encapsulates and stabilizes various therapeutic agents like mRNA, siRNA, proteins, and gene-editing tools, enabling precise delivery to hard-to-reach tissues such as cartilage, kidneys, and solid tumors. This approach enhances therapeutic efficacy, reduces systemic exposure, and preserves bioactivity, offering a low-cost, scalable alternative to existing treatments for chronic conditions.

Amphix Bio specializes in the development of therapeutic materials aimed at advancing regenerative medicine. The company focuses on creating nanofiber materials that replicate the structure and dynamic properties of human tissues. By integrating biological signals into these materials, Amphix Bio effectively guides cells to initiate regenerative processes. This innovative approach enables the development of therapies for repairing various tissues, including bone, cartilage, muscle, cardiovascular tissues, and nervous system components such as the brain and spinal cord. With expertise in materials science, stem cell biology, biomolecular design, engineering, medical physics, and informatics, Amphix Bio seeks to translate its promising preclinical and clinical trial results into viable treatment options.

Eradivir is a biotechnology company based in West Lafayette, Indiana. Founded in 2020, it focuses on developing a non-immunological targeting agent to combat the virus causing COVID-19.

The Wake Forest Institute for Regenerative Medicine (WFIRM) is a leader in translating scientific discovery into clinical therapies. Physicians and scientists at WFIRM were the first in the world to engineer laboratory-grown organs that were successfully implanted into humans. Today, this interdisciplinary team is working to engineer more than 30 different replacement tissues and organs and to develop healing cell therapies-all with the goal to cure, rather than merely treat, disease.

The Wistar Institute is a leading independent biomedical research institution dedicated to advancing medical knowledge through innovative research and training. Established as the first of its kind in the United States, it has grown from an anatomical teaching museum into a prominent center for basic biomedical research. Designated as a National Cancer Institute Cancer Center in 1972, The Wistar Institute focuses on critical areas such as cancer, immunology, and infectious diseases. Its groundbreaking discoveries have contributed to the development of vaccines for diseases like rabies, rubella, and rotavirus, as well as the identification of genes related to breast, lung, and prostate cancer. The Institute promotes a collaborative research environment aimed at addressing some of the most pressing challenges in the biomedical field.

MelliCell is a biotechnology company focused on addressing chronic diseases through innovative tissue engineering technology that targets fat cells. The company’s platform enables the conversion of human stem cells into mature fat cells, facilitating their accelerated growth to sizes that surpass conventional limits. This technology aims to shrink fat cells and improve metabolic health, making it applicable for treating conditions such as obesity, diabetes, aging, oncology, and inflammation. MelliCell’s experienced team is developing oral small molecules that not only decrease fat mass but also reverse disease hallmarks while preserving lean mass. The efficacy of MelliCell’s technology has been recognized through various awards and partnerships with leading biopharmaceutical firms, highlighting its potential to enhance health outcomes and quality of life for individuals worldwide.

Theromics Inc., founded in 2016, develops innovative cell therapies. It specializes in HeatSYNC Gel, a biopolymer thermal accelerant that enhances microwave and radiofrequency energy absorption during soft tissue ablation procedures. This gel amplifies heat movement, optimizes ablation zone shape, increases treatment area, and protects critical tissues.

The Wake Forest Institute for Regenerative Medicine (WFIRM) is a leader in translating scientific discovery into clinical therapies. Physicians and scientists at WFIRM were the first in the world to engineer laboratory-grown organs that were successfully implanted into humans. Today, this interdisciplinary team is working to engineer more than 30 different replacement tissues and organs and to develop healing cell therapies-all with the goal to cure, rather than merely treat, disease.

Astria Biosciences, based in Pittsburgh, specializes in developing innovative diagnostic and therapeutic solutions for cerebrovascular diseases. The company focuses on addressing neurosurgical challenges through molecular biology, advanced analytics, and small-molecule inhibitors, aiming to provide non-surgical alternatives for neurovascular conditions where surgery is currently the primary option.

CerFlux develops advanced cancer modeling technology to enhance understanding and treatment of cancer. Its platform uses innovative ex vivo models to evaluate therapeutic efficacy on patient tumor tissue, enabling oncology professionals to improve patient outcomes through tailored therapy approaches.

Remedium Bio is a Boston-based gene therapy company dedicated to developing curative treatments for a variety of debilitating conditions. The company employs a unique approach that combines established technologies in innovative ways to address well-defined disease mechanisms. By modularly applying these proven technologies, Remedium Bio focuses on creating localized and targeted therapies centered on clinically validated molecules and pathways. Its pipeline includes leading gene therapy candidates in multiple fields, such as rheumatology, endocrinology, and neurology, aimed at providing effective treatments for a range of immune, age-related, and metabolic disorders.

BLOCKsyncop is a company focused on developing innovative clinical monitoring devices aimed at enhancing anesthesiology practices. Its primary product is a non-invasive, real-time tool designed to objectively measure and quantify the effectiveness of neural blocks for pain management. This technology assists anesthesiologists in reducing the occurrence of failed neural blocks, minimizing anesthetic toxicity, and optimizing the analgesic requirements for patients. By providing precise data, BLOCKsyncop aims to improve patient outcomes in pain management and support healthcare professionals in delivering safer and more effective anesthesia care.

Vivifi Medical develops a laparoscopic device that enables quick connection of two blood vessels. Headquartered in Houston, Texas.

Sharper Sense develops wearable neurotechnology to enhance vision, hearing, and touch. The company focuses on a neuromodulation patch that delivers non-invasive electrical stimulation to improve sensory acuity and perception, with potential applications for processing disorders and sensory loss, and to boost performance, enabling clearer, more accurate perceptions for improved task precision and safety.

BioSuperior Technology is a preclinical biotherapeutics company specializing in lung disease treatments. It has developed a novel, synthetic pulmonary surfactant prototype called BioSurf, which mimics the body's natural surfactant to facilitate breathing and deliver therapeutic drugs. This non-invasive, cost-effective technology aims to restore normal lung function and repair damaged lung tissue. Additionally, BioSuperior's platform has potential applications in treating other microvasculature-related illnesses, such as hemorrhagic stroke and chronic kidney disease.

Bespoke Biotherapeutics provides an effective natural immune response and overcomes the limitations of currently approved immunotherapies against cancer by inventing novel, customised living drugs called engineered B-cell therapeutics. They offer customised B-cell sourcing, isolation, activation, culture expansion, and non-viral genetic engineering methodologies uniquely suited to optimise commercial B-cell products for infusion.

Tiny Cargo specializes in the isolation and application of exosomes derived from bovine milk. Their technology enables industrial-scale production of these exosomes for various purposes, including pharmaceutical drug delivery, skin repair treatments, and nutritional applications.

Founded in Baltimore, Maryland in 2018, OncoSTING develops innovative therapies for bladder cancer. The company combines the potency of standard BCG immunotherapy with long-lived delivery of potent STING agonists to enhance immune response and improve safety profiles.

Oculogenex is a biopharmaceutical company founded in 2020 and based in La Habra, California. It specializes in the development of gene therapies aimed at treating retinal disorders. The company’s innovative approach involves ocular regenerative gene therapy that protects retinal pigment epithelial cells from oxidative stress-induced cell death, a condition linked to macular degeneration. By focusing on these therapies, Oculogenex seeks to enable researchers to enhance the detection and treatment of retinal-related disorders, contributing significantly to advancements in this critical area of medical research.

Oxalo Therapeutics develops therapies to treat rare kidney diseases and prevent recurrent oxalate-related stones, focusing on primary hyperoxaluria and other oxalate pathologies. It leverages microbiome science, translational research, and early-stage technology to create a gut-derived therapy that safely removes oxalate from the body, reducing stone recurrence and related renal complications.

EzraBio is a biotechnology company focused on enhancing ribosome profiling for researchers across various biological samples. The company specializes in RNA adenylation technology, which facilitates efficient and rapid cDNA library construction. By offering streamlined services that encompass sample preparation and deep sequencing, EzraBio aims to simplify the ribosome profiling process. This innovative approach allows medical professionals to uncover hidden coding potential, analyze translational responses, identify tumor-associated antigens, and advance mRNA therapeutics. Through its cutting-edge solutions, EzraBio supports researchers in their quest to deepen understanding of complex biological mechanisms.

Creative BioTherapeutics is a biotechnology company dedicated to developing innovative therapies targeting the root causes of cancer affecting immune evasion and drug resistance. Its focus is on recurrent and drug-resistant cancers, aiming to provide effective treatments for adult and childhood cancers.

Simmbion develops a revolutionary system that manufactures therapies within the human body, acting as a 'living pharmacy'. This innovative approach aims to overcome challenges associated with traditional drug delivery methods such as complex manufacturing processes, repeated injections, and high costs. By creating adaptable, reversible cell therapies resistant to supply chain disruptions, Simmbion strives to provide affordable and equitable healthcare solutions globally.

AccuBreath specializes in developing innovative respiratory care solutions. Their flagship product is an affordable, high-end, ultraportable ventilator designed for gentle and portable respiratory support during medical procedures.

Iaso Therapeutics is a therapeutics company established in 2018 and located in East Lansing, Michigan. The company specializes in the development of vaccines aimed at improving human health and addressing infectious diseases. Its platform is designed to create vaccines targeting various deadly infections, including smallpox, yellow fever, and tetanus. By focusing on innovative vaccine technologies, Iaso Therapeutics seeks to equip healthcare professionals with effective tools to combat diseases and enhance overall public health.

Hypersound Medical is focused on developing non-invasive neuromodulatory devices that utilize neurostimulation techniques to address chronic pain conditions. The company's products employ microwave energy to stimulate nerve cells, offering pain relief for various ailments, including arthritis, back pain, and neuropathic pain. By enhancing pain management, Hypersound Medical aims to improve patient function and reduce reliance on pain medication. Their approach encompasses various stimulation methods, such as peripheral nerve stimulation and spinal cord stimulation, positioning the company as a key player in the field of pain relief technology.

Amphix Bio specializes in the development of therapeutic materials aimed at advancing regenerative medicine. The company focuses on creating nanofiber materials that replicate the structure and dynamic properties of human tissues. By integrating biological signals into these materials, Amphix Bio effectively guides cells to initiate regenerative processes. This innovative approach enables the development of therapies for repairing various tissues, including bone, cartilage, muscle, cardiovascular tissues, and nervous system components such as the brain and spinal cord. With expertise in materials science, stem cell biology, biomolecular design, engineering, medical physics, and informatics, Amphix Bio seeks to translate its promising preclinical and clinical trial results into viable treatment options.

Acrigen Biosciences is focused on advancing gene editing technologies to enhance the safety and efficiency of CRISPR-Cas based systems. Founded in 2019 and headquartered in Berkeley, California, the company develops precision gene editing solutions aimed at producing effective and safe in vivo drug therapies for various diseases. Acrigen's innovations include Acro proteins that regulate the CRISPR-Cas gene editing process, along with a bioinformatics discovery software platform designed to identify suitable CRISPR systems for human therapeutic applications. By improving anti-CRISPR proteins and optimizing genetic therapies, Acrigen aims to contribute significantly to the field of medicine and the treatment of debilitating conditions.

Window Therapeutics discovers and develops transformational therapeutics to address unmet patient needs in cancer and other life-threatening diseases. The company focuses on oncology therapies designed to penetrate diseased tissue and exert activity against cancer cells while sparing healthy tissue, leveraging proprietary technology to enhance drug efficacy and reduce toxicity. By advancing targeted treatments, Window Therapeutics aims to improve clinical outcomes and offer new options for patients facing difficult-to-treat cancers.

Nostopharma specializes in treating pathologic bone growth to prevent rare bone diseases. Their nanoparticle drug delivery system aids patients in forming new bone following surgeries, burns, injuries, and other traumas, enabling healthcare providers to enhance clinical outcomes.

Isolere Bio, established in 2018, is a healthcare company specializing in biotherapeutic purification. Its core business involves simplifying and optimizing the manufacturing process of monoclonal antibodies and Adeno-Associated Viruses (AAVs) using Tangential Flow Filtration (TFF) technology. This streamlined approach aims to enhance global access to these vital drugs and research tools, while facilitating a seamless transition from laboratory-scale production to industrial-level output.

Auctus Biologics is a pre-clinical biotechnology company that develops antibody mimetic scaffolds for therapeutic and diagnostic applications. The company is engineering a ribose-binding protein to bind clinical targets with an affinity comparable to monoclonal antibodies while offering enhanced stability that allows survival in extreme environments, including repeated boiling cycles. This approach aims to address antibodies' liabilities, such as instability and costly cold-chain requirements, in order to enable advanced treatments and reduce overall treatment costs.

Reselute specializes in designing, developing, and validating innovative medical devices. Their primary focus is on creating orthopaedic spacers that enhance the treatment of implant-related infections, enabling healthcare professionals to accelerate recovery and improve patient care.

Oncurie is a biotechnology company focused on developing targeted radionuclide therapy aimed at treating metastatic cancer. Utilizing innovative molecular radionuclide technology, Oncurie seeks to deliver radionuclides selectively to metastatic tissues, thereby enhancing treatment efficacy and improving patient outcomes. The company's goal is to provide healthcare providers with advanced therapeutic options that may lead to a cure for various forms of metastatic cancer, including breast cancer. Through its research and development efforts, Oncurie is committed to transforming cancer treatment and addressing unmet medical needs in oncology.

CereVu Medical specializes in developing advanced medical devices. Their primary product is a wearable, single-use forehead patch connected to a reusable console, designed to monitor and analyze cerebral hemodynamics in real-time. This system employs proprietary algorithms to provide continuous pain score assessments, enabling healthcare professionals to tailor treatments based on individual patient needs.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative gene therapy treatments for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes advanced oral lipid nanoparticle technology to deliver mRNA and plasmid DNA directly to intestinal stem cells. This approach aims to address the root causes of gastrointestinal diseases, including Familial Adenomatous Polyposis (FAP), a hereditary condition that can lead to colorectal cancer and often necessitates invasive surgical interventions. DNALite's therapies seek to transform protein biologics into oral drugs, allowing for more effective and less invasive treatment options.

IntuiTap Medical is a medical device company that develops a handheld system to guide spinal puncture procedures. The device aims to eliminate guesswork, frustration, and pain associated with spinal taps by integrating spine imaging, needle guidance, and analytics to enable accurate needle placements for lumbar punctures, spinal anesthesia, and epidurals. The system seeks to improve procedure efficiency and reduce costs while enhancing clinician confidence and patient experience. The company was founded in 2016 and is headquartered in Houston, Texas.

MBF Therapeutics, Inc. is a veterinary oncology company based in Ambler, Pennsylvania, focused on developing and commercializing innovative therapies for cancer treatment in dogs and cats. The company specializes in targeted immunotherapies and small molecule drugs that effectively disrupt tumor cell metabolism while preserving healthy cells and organs. Its product portfolio includes MBFT-101, a combination therapy for sarcomas and lymphoma, featuring a proprietary polyamine transport inhibitor and a potent inhibitor of ornithine decarboxylase, as well as MBFT-102, an immunotherapy based on the tumor suppressor/cytokine mda-7/IL24, which has shown promise in human cancers. Additionally, MBF Therapeutics employs a proprietary DNA vaccine platform and delivery system to develop immunotherapeutic vaccines aimed at enhancing protective immunity against infectious diseases in companion animals and livestock. The company maintains a strategic partnership with the Lankenau Institute for Medical Research to further advance its research and development initiatives.

Vulcan Biologics, established in 2019 and based in Irvine, California, specializes in biotechnology solutions for modulating microbiomes. Its core platform employs bacteriophages, which selectively target and alter specific gut bacteria without affecting the human host, aiming to achieve stable and persistent changes in the microbiome. This approach is primarily focused on treating gluten-related disorders, including gluten sensitivity and celiac disease.

Astek Diagnostics is a healthcare company that develops precision diagnostic technology aimed at improving the diagnosis and treatment of bacterial infections. The company has created a platform that assists physicians in prescribing the correct antibiotics for patients suffering from bacterial sepsis within one hour. Utilizing a single-use cartridge, Astek Diagnostics' device identifies bacterial infections in urine by measuring the oxygen consumption of bacterial species, significantly reducing the turnaround time for results. This innovative approach not only facilitates timely treatment but also helps combat antibiotic resistance through effective susceptibility testing.

Akttyva Therapeutics develops targeted therapeutics to address cell barrier dysfunction across multiple indications.

Averto Medical specializes in the manufacture of medical devices designed to improve outcomes for patients with gastrointestinal diseases. Their innovative solutions aim to facilitate minimally invasive colorectal tumor removal and other gastrointestinal surgeries, enabling healthcare professionals to provide optimal care.

CorInnova Incorporated, founded in 2004 and based in Houston, Texas, specializes in device-based therapies aimed at treating congestive heart failure. The company is known for its innovative non-blood-contacting soft robotic cardiac assist device, which has the potential to significantly increase the number of heart failure patients eligible for life-saving device therapies. By focusing on advanced technological solutions, CorInnova seeks to improve outcomes for individuals suffering from this serious condition.

Nasus Medical specializes in developing innovative, non-invasive drug-delivery devices aimed at improving the treatment of chronic sinusitis. Their flagship product enables patients to self-administer medication rapidly and conveniently, reducing the need for oral medications with systemic side effects, injections by healthcare professionals, or costly surgical procedures. This approach aims to enhance patient comfort, convenience, and outcomes while lowering overall healthcare costs.

OPOS specializes in opioid treatment for patients, ensuring regulatory compliance. Its platform reduces administrative burden, minimizes prescribing risks, and optimizes patient outcomes by providing clinical decision support.

BioSapien is a biotechnology company developing innovative, biodegradable implantable devices that deliver pharmaceuticals directly to cancer sites. Its flagship product, MediChip, uses 3D printing technology to create a mesh capable of sustained drug release, reducing systemic side effects and improving patient care.

Felix Biotechnology, Inc. is a San Francisco-based company founded in 2019 that specializes in developing biotherapeutics to combat microbial challenges in human health. The company focuses on creating treatments for antibiotic-resistant strains of bacteria and fungi, aiming to address the urgent need for effective management of infectious diseases. By accelerating the deployment of novel biotherapeutics, Felix Biotechnology seeks to provide healthcare professionals with precise and effective tools to tackle these pressing health issues.

Biochip Labs is a company based in Cleveland, Ohio, founded in 2019. It specializes in providing laboratory testing services focused on blood disorders, particularly sickle cell disease and thalassemia. The company offers a range of proprietary microfluidic biomarker assays, including tests for blood cell adhesion, red blood cell deformability, whole blood rheology, and endothelialized microfluidics. These assays are designed to evaluate the effectiveness of emerging targeted and curative therapies, allowing clinicians to monitor patients' responses to treatment accurately.

Niche Biomedical is a platform and therapy development firm that specializes in innovative treatments for chronic injuries and disorders that have not responded to conventional pharmacological methods. The company has developed the ExaStim, a non-invasive neuromodulation system designated as an FDA Breakthrough Device, aimed at treating spinal cord injuries. Additionally, Niche Biomedical is working on a gastrointestinal therapeutic device designed to alleviate postoperative ileus and restore gastrointestinal motility. This device leverages bioelectronic medicine to address diseases and injuries that are resistant to pharmaceutical therapies. The firm is also capable of creating miniaturized implantable devices with advanced functionalities, allowing for diverse electrode configurations to enhance treatment options through neuromodulation.

Kodikaz Therapeutic Solutions develops a genomic transfer delivery platform for RNA and DNA delivery vectors, aiming to move beyond conventional cancer therapies toward durable cures through targeted gene transfer. Its Zip-Code technology is a cell-specific delivery system derived from an endogenous human mechanism, designed to avoid the challenges of viral delivery and to be applicable across multiple cell types. The company translates cell-recognition and genomic integration mechanisms identified in human cancers into practical therapies, generating both in vitro and in vivo data in oncology to support the development of cell-targeted gene transfer technologies into curative treatments. Applications include cancers such as pancreatic cancer, multiple myeloma, and colorectal cancer, and the platform supports collaborations to help clients develop cell-specific gene transfer approaches.

TheraCea Pharma is a biotechnology company specializing in precision medicine for neurological disorders. Based in Tucson, Arizona, it develops and licenses radiochemistry technology enabling high-efficiency fluorine-18 radiolabeling of biomolecules for clinical and research applications.

TRGel is a biotechnology company founded in 2010 and based in Irvine, California, specializing in the development of glucose-based biopolymers that serve as alternatives to calcium alginate for encapsulation purposes. The company's biopolymers are crafted from biocompatible materials and include thermoresponsive hydrogels with adjustable gelation temperatures. This innovative approach allows researchers to effectively use TRGel's biopolymers as vehicles for drug delivery, enhancing the potential for various therapeutic applications.

ZelosDx is a company focused on developing neurodiagnostic technologies, specifically blood testing products aimed at advancing research in brain health and disease. It offers proprietary technology that allows research collaborators to license and adapt blood testing kits and automated laboratory equipment. Additionally, the company provides pharmaceutical partners with biomarker technology essential for drug discovery tools. By delivering critical data for diagnosis, monitoring, and assessing therapeutic responses, ZelosDx supports researchers and pharmaceutical companies in making significant breakthroughs in understanding and treating brain-related conditions.

Nano PharmaSolutions specializes in enhancing the bioavailability of insoluble drugs through its proprietary nanoformulation technology. The company has developed an innovative phase-transition technology platform that significantly improves the solubility of BCS 2 and BCS 4 active pharmaceutical ingredients (APIs) without the need for excipients, which are typically used in traditional processes like spray-dry dispersion and emulsification. By vaporizing the API and depositing it onto a carrier molecule, Nano PharmaSolutions enables the production of nanoparticles that can be processed into various dosage forms. Additionally, the company focuses on delivering neurodegenerative therapeutics directly to the brain via an intranasal route, facilitating a rapid onset of action and enhancing safety profiles. Their pipeline includes treatments for conditions such as Parkinson's disease, peripheral neuropathy, and substance abuse disorders, positioning Nano PharmaSolutions as a key player in the field of nanomedicine.

HC Simulation, founded in 2011 and based in Canton, Mississippi, focuses on developing advanced products that utilize the HumMod engine to deliver high-quality simulations of human physiology. The company's offerings enable users to explore physiological interactions that may be difficult to observe in traditional settings. By providing a platform for realistic modeling, HC Simulation supports the ideation, development, and prediction processes for innovative medical devices and pharmaceuticals.

LumenAstra, established in 2020 and headquartered in Longmont, Colorado, specializes in the development of non-invasive, wearable deep-tissue temperature sensors. These devices are designed to accurately measure internal temperatures from external locations, serving diverse applications such as cancer hyperthermia therapy, hypothermia for aortic dissection repair, brain temperature monitoring for newborns, and heat stress monitoring in high-risk environments like military operations or hazardous workplaces. The company's innovative sensor technology enables medical professionals to better protect patients from potential harm caused by extreme temperatures.

MedChem Partners is a medicinal chemistry CRO that specializes in developing small molecule therapeutics. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.

SingletO2 Therapeutics, established in 2015 and based in New Providence, New Jersey, focuses on developing innovative treatments for periodontal disease. The company leverages the potent bacteria-killing properties of singlet oxygen to create therapies that can address advanced stages of the disease without the need for surgical intervention.

Theromics Inc., founded in 2016, develops innovative cell therapies. It specializes in HeatSYNC Gel, a biopolymer thermal accelerant that enhances microwave and radiofrequency energy absorption during soft tissue ablation procedures. This gel amplifies heat movement, optimizes ablation zone shape, increases treatment area, and protects critical tissues.

Drive Therapeutics is a biotechnology company focused on developing therapies for retinal diseases. It develops treatments for wet age-related macular degeneration and diabetic retinopathy/diabetic macular edema, aiming to improve therapeutic efficacy while reducing dosing frequency to achieve better patient outcomes in retinal care.

Founded in 2018, Paramita Therapeutics is a biotechnology company based in San Diego, California. It specializes in developing new therapeutics for cancer and infectious diseases.

ALSUS MEDICAL offers treatment for urinary stream problems that may be weak or stop and start. In some cases, it can lead to infection, bladder stones, and reduced kidney function. They offer treatments that include medication that relaxes or shrinks the prostate, surgery, and minimally invasive surgery.

InSoma Bio integrates biology and materials science to solve problems in tissue engineering and regenerative medicine. It offers genetically engineer protein-based materials that can mimic the naturally found elastin found in extracellular tissues. The company also offers reconstructive plastic surgeries and injectable materials.

Cordance Medical is a medical device company focused on innovative therapies for central nervous system (CNS) conditions, including primary and metastatic cancers, Alzheimer's disease, and Parkinson's disease. The company has developed a non-invasive ultrasound system specifically designed to open the blood-brain barrier. This low-power ultrasound technology allows for precise and reversible openings of the blood-brain barrier, facilitating targeted delivery of systemically administered medications to specific brain regions. By enhancing access to the brain for therapeutic agents, Cordance Medical aims to create new diagnostic and treatment options for patients suffering from various CNS pathologies.

Avior Bio is a clinical-stage pharmaceutical company focused on developing innovative therapies for distressed neurological conditions and associated symptoms, including pruritus resulting from liver disease. The company utilizes its proprietary Speedit™ Transmucosal Film Technology, which enhances drug delivery by avoiding first-pass metabolism and significantly reducing glucuronide metabolites excreted by the kidneys. This technology aims to provide effective relief from various conditions, such as insomnia, anxiety, depression, and skin excoriation, thus offering improved efficacy and safety for patients. With a strong management team, an experienced advisory board, and a dedicated group of scientists and clinicians, Avior Bio is well-positioned to advance its mission of delivering high-value therapeutic solutions.

Founded in 2021 and based in South San Francisco, California, Tacit Therapeutics develops RNA-targeted treatments aimed at repairing mutated genes. The company innovates by repurposing existing human cell components to create broadly applicable, non-immunogenic gene modification methods.

Verantos is the market leader in high-validity real-world evidence for life sciences. By incorporating robust clinical narrative data, artificial intelligence technology, and measured validity, Verantos is the first company to generate research-grade evidence at scale across all therapeutic areas. The Verantos Evidence Platform integrates heterogeneous real-world data sources and generates evidence with the accuracy necessary for market access, HEOR, medical affairs, and regulatory use.

Partillion Bioscience is a life science company developing a platform for functional single-cell analysis. This platform enables rapid compartmentalization and analysis of millions of single cells to probe biological functions such as secreted proteins, facilitating the development of advanced therapies for conditions like cancer, autoimmune disorders, and infectious diseases.

Access Airways is a company that specializes in the development of innovative intubation-delivering devices designed to improve the safety and efficiency of intubation procedures. Their flagship product is a minimally invasive articulating intubation stylet that enhances access to difficult airways, thereby aiming to upscale the standard of care during patient intubation. The device features intuitive capabilities that allow clinicians to perform quicker and less harmful procedures, significantly reducing the time required for intubation and minimizing the risk of failed attempts. Its design enables effortless control and articulation of the tip, allowing for enhanced navigation in challenging airway situations, ultimately benefiting both caregivers and patients.

Midday is an app that leverages AI, sensor technology, and digital therapeutics to support women on their menopause journey using personalized insights that illuminate what is happening physically and emotionally during menopause, providing the right intervention at the right time to manage menopause symptoms and promote healthy aging.

SpheroFill is a drug delivery platform that specializes in creating innovative injectable tissue fillers, specifically designed to address age-related atrophy in the larynx. Utilizing a unique combination of solid, hollow, and porous-wall hollow glass microspheres along with biocompatible and bioactive matrices, SpheroFill enhances drug delivery for healthcare professionals. Its technology enables improved patient compliance by reducing dosing frequency and allows for oral formulations that current technologies cannot achieve. By focusing on the protection, delivery, and controlled release of active pharmaceutical ingredients, SpheroFill represents a significant advancement in the field of drug administration.

NeuroLogic Solutions is a pre-revenue company based in Baltimore, Maryland, founded in 2016. The company specializes in developing smart electroencephalography (EEG) analytic software designed to enhance the diagnosis and treatment of epilepsy. Its platform analyzes EEG data to identify the regions of the brain affected by epilepsy, which aids clinicians in making accurate diagnoses and optimizing treatment plans. By focusing on neuroimaging analytics, NeuroLogic Solutions aims to improve patient outcomes, potentially leading to seizure freedom for individuals with epilepsy.

Founded in 2020, Current Surgical is a medical device company based in Washington, D.C. It specializes in developing precise tools for the treatment of solid tumors, focusing on minimally invasive tumor detection and ablation using smart surgical needles guided by real-time X-ray imaging and ultrasound energy.

NellOne Therapeutics, Inc. is a regenerative medicine company based in Oak Ridge, Tennessee, focused on developing and commercializing protein therapeutics aimed at restoring cardiac muscle mass and function in patients recovering from myocardial infarction and congestive heart failure. The company was established in 2007 as a spin-out from the U.S. Department of Energy's Oak Ridge National Laboratory, where research led by Dr. Cymbeline Culiat identified the Nell1 gene's role in the formation of essential mammalian tissues and organs. NellOne is dedicated to translating these scientific discoveries into clinical applications, specifically by leveraging Nell1 protein therapeutics to rebuild cardiac muscle and improve patient outcomes following heart-related conditions.

Founded in 2019, Precision Theranostics is a biotechnology company headquartered in Baltimore, Maryland. It specializes in developing prognosis-based intervention strategies for the early detection and treatment of fatal diseases, focusing on respiratory diseases and age-related disorders.

Galaxy Therapeutics specializes in neurovascular devices designed to enhance the treatment of cerebral aneurysms. Their innovative device aims to increase cure rates and facilitate easy deployment, offering fluoroscopic visualization for shallow or large aneurysms.

Epivara, established in 2016 and based in Champaign, Illinois, specializes in animal welfare innovations. The company develops a single-injection alternative to traditional spaying and neutering surgery for pets. This non-surgical sterilization method aims to reduce pain, risk, and recovery time compared to conventional procedures, thereby improving the lives of both animals and their owners. Epivara's mission is to enhance animal well-being through innovative science and compassionate care.

FluidForm Bio is a biotechnology company focused on creating living human tissue to improve disease treatment. Utilizing its patented FRESH technology, the company employs 3D printing to construct tissue using cells, proteins, and no other materials. This innovative platform has been validated through partnerships with leading life science companies, enabling the production of high-quality tissue for various applications. FluidForm Bio's advanced techniques integrate breakthroughs in 3D printing, computational and synthetic biology, artificial intelligence, and materials science to deliver human tissue that closely resembles natural tissue. Established in 2018 and headquartered in Waltham, Massachusetts, FluidForm Bio aims to provide transformative therapies that offer better treatment options for patients in need.

Infini Fluidics develops injectable drug delivery systems intended to treat diseases such as cancer and cardiovascular disease. They provide injectable drug delivery systems at an industrial scale on a portable chip, combining microfluidics with semiconductor technology, enabling patients, healthcare providers, and facilities to get access to lifesaving drugs.

Oculogenex is a biopharmaceutical company founded in 2020 and based in La Habra, California. It specializes in the development of gene therapies aimed at treating retinal disorders. The company’s innovative approach involves ocular regenerative gene therapy that protects retinal pigment epithelial cells from oxidative stress-induced cell death, a condition linked to macular degeneration. By focusing on these therapies, Oculogenex seeks to enable researchers to enhance the detection and treatment of retinal-related disorders, contributing significantly to advancements in this critical area of medical research.

Talus Bio is a biotechnology company specializing in drug discovery. It focuses on developing therapies targeting challenging cancer transcription factors using its proprietary MARMOT platform, which integrates functional proteomics, automated biology, machine learning, AI, synthetic chemistry, and computational biology to design and analyze drugs, proteins, and genomics.

Enable Therapeutics is a biotechnology company developing a patented drug delivery platform. The company was founded in 2020 and is headquartered in Hopedale, Massachusetts.

Amberstone Biosciences is a biotechnology company focused on discovering novel immunotherapies aimed at addressing challenging medical targets that traditional methods struggle to tackle. The company utilizes its proprietary microfluidics-powered AmberFlow drug-discovery platform, which allows for the analysis of single-cell function within a customizable microenvironment. This innovative approach, combined with the expertise of its team in immuno-oncology and single-cell assay biology, positions Amberstone to develop transformative therapeutic antibodies that cater to patients with unmet medical needs. Through creative partnerships and advanced technologies, Amberstone Biosciences seeks to overcome conventional limitations in therapeutic development, ultimately enhancing patient care and outcomes.

Nabla Bio is a biotechnology company that uses artificial intelligence and lab technologies to rationally design novel proteins for drug development. They aim to create medicines and improve nutrition by engineering proteins with enhanced qualities.

NeyroblastGX is a biotechnology company based in Murrieta, California, founded in 2020. It specializes in developing theranostic products aimed at treating neurodegenerative and infectious diseases. The company's innovative product portfolio includes a blood-based biomarker diagnostic for Alzheimer's, genetically engineered dendritic cells designed to target custom-made human organoids for drug screening, and an oral supplement that enhances protective immunity. Through its comprehensive range of diagnostics, drugs, and therapies, NeyroblastGX is committed to providing effective solutions for patients facing life-threatening conditions.

Founded in 2016, Cobio Diagnostics is a biotechnology company based in Golden, Colorado. It specializes in developing diagnostics for bacterial identification and phenotypic antibiotic resistance testing using a phage-based immunoassay. This enables healthcare providers to make quicker and more informed decisions about antibiotic use.

Nanoxort develops diffusive magnetic fractionation technology to precisely tailor the properties of magnetic nanomaterials. The company also pursues MRI contrast solutions in which a contrast agent is administered to improve image resolution and reduce gadolinium exposure, addressing safety concerns for patients who require repeated scans and those with kidney impairment. Founded in 2018 and based in Auburn, Alabama, Nanoxort aims to enable safer, higher quality MRI imaging by controlling magnetic nanoparticle behavior and minimizing potential toxic effects associated with gadolinium-based contrast agents.

Florica Therapeutics is a biotechnology company founded in 2019 and based in Livermore, California. The company specializes in the development of exosome-based therapeutics aimed at extending lifespan and preventing diseases associated with aging. Florica's innovative therapeutics focus on delivering drugs to the brain and provide alternatives for treatment of life-altering conditions such as leukemia and Tay-Sachs disease. By leveraging exosome technology, the company aims to offer health institutions access to novel treatments that enhance patient longevity and quality of life.

Gradient Medical develops innovative interventional oncology services focused on bringing Ablative Cancer Electroporation (ACE) therapy to clinical settings. Established in 2020, the company is based in Raleigh, North Carolina.

FibrosIX is a biotechnology company founded in 2016 and based in East Lansing, Michigan. The company focuses on developing small-molecule therapeutics aimed at preventing lung fibrosis in cancer patients. Its innovative drugs target and modulate a critical signaling pathway involved in the development of fibrotic diseases, which can lead to diminished lung function and respiratory issues. By addressing these challenges, FibrosIX aims to enhance the quality of life for patients undergoing cancer treatment.

Nano RED specializes in precision delivery technologies aimed at advancing RNA and immunotherapeutics for cancer treatment. The company develops innovative immunotherapy solutions that utilize liposomes, which are injected into the bloodstream. This approach allows for the direct release of cancer therapies into tumors and their surrounding environments, while also addressing the associated toxicity within the body. Through its cutting-edge technology, Nano RED seeks to enhance the effectiveness of cancer treatments and improve patient outcomes.

NeuroDyne specializes in developing medical technology aimed at diagnosing and treating neurological diseases. The company focuses on creating devices that alleviate seizure activity in children with congenital brain disorders, adults experiencing seizures, and veterans affected by brain damage. By providing innovative solutions, NeuroDyne enables medical professionals to offer effective relief to individuals suffering from the debilitating effects of seizures.

Spirrow Therapeutics provides lung restoration to babies suffering from ARDS by using new proprietary methods. They provide polymer lung surfactant to low complexity synthesis and formulation, interface affinity exceeds competing agents, reduces alveolar surface tension, and fluid accumulation.

GRI Bio is a development-stage biotechnology company focused on discovering and developing therapies that modulate Natural Killer T (NKT) cell activity to treat inflammatory, autoimmune, and fibrotic diseases, including liver disease. Based in La Jolla, California, the company develops cell- and molecule-based approaches to regulate NKT cell function and restore immune homeostasis, with programs such as GRI-0621, an oral agent that inhibits type 1 NKT cell activity, and GRI-0803, a novel oral agonist targeting type 2 NKT cells.

Grit Bio, established in 2017 with its headquarters in New York, NY, is a biotechnology company dedicated to developing safer cancer therapeutics. Its primary focus is on treating pharyngeal squamous cell carcinoma through innovative approaches that aim to block increased lipid metabolism turnover and oncogenic sphingolipid production, thereby enhancing treatment safety and prolonging remission periods for patients.

Spero Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel treatments for multi-drug resistant bacterial infections and rare diseases. Its primary focus is on tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic intended for adult use in treating MDR Gram-negative infections.

iReprogram is a cell regeneration laboratory based in Ann Arbor, Michigan, established in 2017. The company focuses on advancing personalized medicine through innovative cell reprogramming technology. By utilizing a high-fidelity prototype computational tool, iReprogram generates transcription factor recipes that facilitate cellular trans-differentiation, particularly for cancer treatment. This technology aims to enhance the effectiveness of cancer therapies, ultimately allowing patients to benefit from more tailored and effective treatment options.

Eradivir is a biotechnology company based in West Lafayette, Indiana. Founded in 2020, it focuses on developing a non-immunological targeting agent to combat the virus causing COVID-19.

Founded in 2018, Souvie Biodelivery specializes in developing innovative drug delivery systems using engineered exosomes. Its platform aims to enhance biocompatibility, reduce immunogenicity, and improve specificity for targeted treatments across various diseases like immuno-inflammation, cancer, and neurological disorders.

Progenitor MDX is a biotechnology company focused on developing advanced cellular immunotherapy technologies and innovative solutions for managing COVID-19 infections. The company offers a comprehensive approach that includes testing and actionable infection management plans, aimed at providing reassurance to communities. In addition to its COVID-19 management solutions, Progenitor MDX specializes in cellular reprogramming, utilizing a streamlined method that incorporates all Yamanaka factors into a single vector. This technology enables the creation of allogeneic off-the-shelf CAR constructs from various cell sources, facilitating the efficient insertion of multiple genetic elements. By enhancing the industrial workflows for producing engineered cell therapies, Progenitor MDX plays a critical role in advancing immune-oncology and the development of new therapeutic options.